Journal of Molecular Neuroscience

, Volume 24, Issue 1, pp 149–153

Transforming growth factor-β signaling pathway as a therapeutic target in neurodegeneration



Neurodegenerative diseases are becoming an increasing social and economical burden as our population ages; but current knowledge of the processes leading to these diseases is still limited, and no effective treatments are available. Neurodegeneration in Alzheimer’s disease (AD) is the most common cause of dementia and afflicts an estimated 4 million people in this country alone. Because accumulation of β-amyloid (Aβ) peptide appears central to AD pathogenesis, large efforts have been directed at understanding and interfering with Aβ production or aggregation. These efforts have largely identified the processes resulting in Aβ production from the larger amyloid precursor protein (APP) and have revealed that Aβ peptide is also produced at low levels in the healthy brain. Interestingly, Aβ production is rapidly increased after neuronal injury, and traumatic brain injury is a known risk factor for AD and Parkinson’s disease. In contrast, brain injury in young individuals does not seem to result in AD, and brain injury in animal models can promote Aβ clearance. This suggests that certain factors associated with injury might be able to reduce the accumulation of Aβ. Accumulation of Aβ peptide might be reduced either directly by stimulating phagocytes or other Aβ-degrading processes, or indirectly, by reducing neuronal injury and thus lowering the production of Aβ peptide. Directing the brain’s natural mechanisms for clearing Aβ or increasing neuroprotection might therefore be reasonable approaches in interfering with AD pathogenesis.

Index Entries

Cytokine neurodegeneration amyloid TGF-β signaling 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bonyadi M., Rusholme S. A. B., Cousins F. M., et al. (1997) Mapping of a major genetic modifier of embryonic lethality in TGFβ1 knockout mice. Nat. Genet. 15, 207–211.PubMedCrossRefGoogle Scholar
  2. Brionne T. C., Tesseur I., Masliah E., and Wyss-Corray T. (2003) Loss of TGF-beta 1 leads to increased neuronal cell death and microgliosis in mouse brain. Neuron 40, 1133–1145.PubMedCrossRefGoogle Scholar
  3. Chin J., Angers A., Cleary L. J., Eskin A., and Byrne J. H. (2002) Transforming growth factor β1 alters synapsin distribution and modulates synaptic depression in Aplysia. J. Neurosci. 22, 1–6.Google Scholar
  4. Dennler S., Goumans M.-J., and Dijke P. T. (2002) Transforming growth factor β signal transduction. J. Leukoc. Biol. 71, 731–740.PubMedGoogle Scholar
  5. Dnker N., Schuster N., and Krieglstein K. (2001) TGF-β modulates programmed cell death in the retina of the developing chick embryo. Development 128, 1933–1942.Google Scholar
  6. Finch C. E., Laping N. J., Morgan T. E., Nichols N. R., and Pasinetti G. M. (1993) TGF-β1 is an organizer of responses to neurodegeneration. J. Cell. Biochem. 53, 314–322.PubMedCrossRefGoogle Scholar
  7. Flanders K. C., Ren R. F., and Lippa C. F. (1998) Transforming growth factor-βs in neurodegenerative disease. Prog. Neurobiol. 54, 71–85.PubMedCrossRefGoogle Scholar
  8. Gleeson J. G., Allen K. M., Fox J. W., et al. (1998) Doublecortin, a brain-specific gene mutated in human X-linked lissencephaly and double cortex syndrome, encodes a putative signaling protein. Cell 92, 63–72.PubMedCrossRefGoogle Scholar
  9. Johnson E. M., Jr., and Deckwerth T. L. (1993) Molecular mechanisms of developmental neuronal death. Annu. Rev. Neurosci. 16, 31–46.PubMedCrossRefGoogle Scholar
  10. Krieglstein K., Richter S., Farkas L., et al. (2000) Reduction of endogenous transforming growth factors beta prevents ontogenetic neuron death. Nat. Neurosci. 3, 1085–1090.PubMedCrossRefGoogle Scholar
  11. Letterio J. J. (2000) Murine models define the role of TGF-β as a master regulator of immune cell function. Cytokine Growth Factor Rev. 11, 81–87.PubMedCrossRefGoogle Scholar
  12. Massagué J., Blain S. W., and Lo R. S. (2000) TGF-β signaling in growth control, cancer, and heritable disorders. Cell 103, 295–309.PubMedCrossRefGoogle Scholar
  13. Roberts A. B. and Sporn M. B. (1996) in The Molecular and Cellular Biology of Wound Repair, Clark, R. A. F., ed., Plenum Press, New York, pp. 275–308.Google Scholar
  14. Sweeney S. T. and Davis G. W. (2002) Unrestricted synaptic growth in spinster-a late endosomal protein implicated in TGF-beta-mediated synaptic growth regulation. Neuron 36, 403–416.PubMedCrossRefGoogle Scholar
  15. Unsicker K. and Krieglstein K. (2002) TGF-betas and their roles in the regulation of neuron survival. Adv. Exp. Med. Biol. 513, 353–374.PubMedGoogle Scholar
  16. Weinstein M., Yang X., and Deng C.-X. (2000) Functions of mammalian Smad genes as revealed by targeted gene disruption in mice. Cytokine Growth Factor Rev. 11, 49–58.PubMedCrossRefGoogle Scholar
  17. Wyss-Coray T., Lin C., Yan F., Yu G., Rohde M., McConlogue L., Masliah E., and Mucke L., et al. (2001) TGF-β1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice. Nat. Med. 7, 614–618.CrossRefGoogle Scholar
  18. Zhang F., Endo S., Cleary L. J., Eskin A., and Byrne J. H. (1997) Role of transforming growth factor-β in long-term synaptic facilitation in Aplysia. Science 275, 1318.PubMedCrossRefGoogle Scholar
  19. Zheng X., Wang J., Haerry T. E., et al. (2003) TGF-beta signaling activates steroid hormone receptor expression during neuronal remodeling in the Drosophila brain. Cell 112, 303–315.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc 2004

Authors and Affiliations

  1. 1.Department of Neurology and Neurological SciencesStanford University School of MedicineStanford
  2. 2.GRECC, VA Palo Alto Health Care SystemPalo Alto

Personalised recommendations